- Trial phase
- Phase 1/2
- Time to market
- Likely years away. The QUADvance Phase I/II trial's primary completion is estimated for April 2029. Even with potential accelerated development, regulatory filing would be at least several years away given the Phase 1a dose-escalation stage.
- Why 1/10
- No hard, dated binary catalyst (PDUFA, pivotal readout, AdComm) exists for AVC-203 within the next ~12 months. The Phase I/II QUADvance study is in early dose escalation (first patient dosed April 2026) with primary completion estimated at April 2029. For LGND, this is one of 200+ royalty assets and represents a small financial commitment ($41M total, paid in milestone-tied tranches). The next meaningful event would be early safety/efficacy data from Phase 1a, but no date is set.
AVC-203 is in very early clinical testing (Phase 1a dose escalation), with no hard-dated binary catalysts on the horizon. The primary completion of the QUADvance study is estimated for April 2029. For LGND investors, this program is a minor, early-stage royalty interest among over 200 assets in Ligand's portfolio; watch for any early Phase 1a data disclosures at medical meetings, but the near-term stock thesis for LGND is determined by its established royalty portfolio and earnings trajectory, not this single program.
Price Chart
Executive Summary
AVC-203 is a CRISPR-engineered allogeneic (off-the-shelf) CAR-T cell therapy being developed by private company AvenCell Therapeutics for relapsed or refractory B-cell malignancies (lymphomas and leukemias). It simultaneously targets CD19 and CD20 to reduce the chance of cancer relapse via antigen escape. The QUADvance Phase I/II trial received FDA IND clearance and EMA approval in December 2025, and the first patient was dosed in April 2026. Ligand Pharmaceuticals (Nasdaq: LGND) holds a financial interest via a September 2026 royalty financing agreement: up to $41 million committed in milestone-tied tranches in exchange for a mid-single-digit to low-double-digit royalty on worldwide net sales of AvenCell's pipeline, including AVC-203. For LGND, this is a small, early-stage, non-binary royalty interest within a portfolio of over 200 assets. No near-term pivotal catalysts are scheduled for AVC-203, and the primary completion of the Phase I/II study is estimated for April 2029.
How It Works
AVC-203 is an 'off-the-shelf' cell therapy made from healthy donor immune cells (T-cells) that have been genetically edited using CRISPR to target and kill cancer cells. It simultaneously targets two proteins on B-cell cancers called CD19 and CD20, which is designed to reduce the chance that cancer cells evade treatment by losing one target. The 'allogeneic' approach means these cells are pre-manufactured from healthy donors and ready to use immediately, unlike current CAR-T therapies that require extracting, engineering and reinfusing a patient's own cells, a process that takes weeks. A safety 'switch' is built in to allow deactivation if needed.
Trial Status
The FDA and EMA cleared the Phase I/II QUADvance study in December 2025. The first patient was dosed in April 2026, making it the first CRISPR-engineered allogeneic dual-targeting CD19/CD20 switchable CAR-T to enter clinical testing. The study is actively recruiting at multiple sites in the US and Europe, with planned expansion to Japan. The estimated primary completion date is April 2029.
The Two-Sided Case
Upcoming Catalysts
- No hard-dated catalysts are scheduled. The next meaningful event would be early Phase 1a safety/efficacy data from the QUADvance dose-escalation portion, potentially disclosed at medical conferences in 2027-2028. Ligand's milestone payments tied to AvenCell's clinical progress are not publicly dated events.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Ligand Pharmaceuticals PRESS-RELEASE LGND ·Originating report